Mazdutide outperforms Semaglutide in T2D and obesity trial Mazdutide, the dual GCG/GLP-1RA, significantly improving blood glucose control & weight loss over Semaglutide
Considering that and -cells express GIPR (224) and that the GIP-potentiating activity of Xenin has been reported to be lost in human diabetics (223), it appears to be a critical player in this disease, likely involving the activity of GLP-1
Comment below, share this, and lets connect to strategize
Similar glycemic control in the 2 treatment groups was desired in order to not confound the interpretation of the retinal data
Instead of following the standard titration schedule, microdosing involves starting at sub-therapeutic doses, often 0.5mg to 1.25mg, and increasing in very small increments
You must demonstrate that youve completed a structured weight-management program (including diet, exercise, and behavioral support) for at least 6 months prior to starting Wegovy